Following on from information provided to NICE by the company in January 2019, the appraisal of Lubiprostone for treating opioid-induced constipation in people with chronic, non-cancer pain [646] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | 28 January 2014 |
| 1st appraisal committee meeting: | 07 May 2014 |
Project Team
| Communications manager: | TBC |
| Project manager: | |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 31 October 2022 | Following on from information provided to NICE by the company in January 2019, the appraisal of Lubiprostone for treating opioid-induced constipation in people with chronic, non-cancer pain [646] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 31 October 2022 | Discontinued. Following on from information provided to NICE by the company in January 2019, the appraisal of Lubiprostone for treating opioid-induced constipation in people with chronic, non-cancer pain [646] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 17 February 2021 | This guidance is no longer progressing because Takeda has discontinued lubiprostone (Amitiza). |
| 04 April 2014 | 7 May 2014 -Committee meeting for this appraisal topic has been cancelled. The appraisal is suspended because the regulatory timeline has changed due to the MHRA not granting a license for this indication. The appraisal topic will be rescheduled into the NICE work programme when the regulatory next steps are known.’ |
For further information on our processes and methods, please see our CHTE processes and methods manual